Clinical trial
XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or…
NCT00212615 · Odense University Hospital, Other · Completed
Key facts
| NCT number | NCT00212615 |
|---|---|
| Title | XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer |
| Official title | XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study |
| Lead sponsor | Odense University Hospital, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | C04.588.274.476.411.307 |
| Intervention type | Drug |
| Interventions | Oxaliplatin (Eloxatin), Capecitabine (Xeloda) |
| Enrollment | 116 |
| Start date | Feb 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 6, 2020 |
| Countries | Denmark, Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: